ArticleOpen forum infectious diseases2021
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
Open access · goldAbstract read
In one paragraph
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Multicenter Evaluation of Ceftazidime/Avibactam in Pediatric Patients Across the United States: Real-World Insights into the Management of Drug-Resistant Gram-Negative Infections.Open forum infectious diseases · 2026Trial
- Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports.Journal of blood medicine · 2026Article
- Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.JAC-antimicrobial resistance · 2025Review
- Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.Antibiotics (Basel, Switzerland) · 2025Review
- Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.Le infezioni in medicina · 2025Article
- Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).Infectious diseases and therapy · 2025Article
- Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.Life (Basel, Switzerland) · 2024Review
- Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.Current therapeutic research, clinical and experimental · 2024Review
- Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producingFrontiers in microbiology · 2024Article
- First case report of a vertebral osteomyelitis caused by carbapenem-resistantFrontiers in pharmacology · 2024Article
- Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.Open forum infectious diseases · 2023Article
- Novel Antimicrobial Agents for Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- Impact ofJAC-antimicrobial resistance · 2023Article
- Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.Antibiotics (Basel, Switzerland) · 2022Review
- Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2022Review
- New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.Antimicrobial agents and chemotherapy · 2022Review
- New Drugs for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.Antibiotics (Basel, Switzerland) · 2022Review
- Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.Frontiers in cellular and infection microbiology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 1 country.
Nicholas ReboldAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-5469-1228
Taylor MorrisetteAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-1094-043X
Abdalhamid M LagnfAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Sara AlosaimyAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0001-8349-7531
Dana HolgerAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Katie BarberDepartment of Pharmacy, University of Mississippi Medical Center, Jackson, Mississippi, USA.ORCID https://orcid.org/0000-0002-8411-3111
Julie Ann JustoClinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.ORCID https://orcid.org/0000-0002-4161-9577
Kayla AntoszDepartment of Pharmacy, Prisma Health-Midlands, Columbia, South Carolina, USA.
Travis J CarlsonDepartment of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, North Carolina, USA.ORCID https://orcid.org/0000-0001-9564-3030
Jeremy J FrensDepartment of Pharmacy, Moses H. Cone Memorial Hospital, Cone Health, Greensboro, North Carolina, USA.
Mark BiagiCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-5190-0066
Wesley D KufelDepartment of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.ORCID https://orcid.org/0000-0001-7703-096X
William J MooreDepartment of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
Nicholas MercuroDepartment of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7619-8736
Brian R RauxDepartment of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0003-0183-216X
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0003-2220-0081
Eugene Applebaum College of Pharmacy and Health Sciences · USPrisma Health · USBeth Israel Deaconess Medical Center · USBinghamton University · USCone Health · USHigh Point University · USMedical University of South Carolina · USNorthwestern Memorial Hospital · USSwedish American Hospital · USUniversity of Mississippi Medical Center · US
Funding
A Pharmacologic Approach to Prevent Daptomycin Resistance in VRER01AI121400 · NIAID · WAYNE STATE UNIVERSITY · PI RYBAK, MICHAEL JOSEPH · 2016 to 2020
$1.9MNIAID NIH HHS R01 AI121400
Abstract
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was
Indexed as
carbapenem-resistant Enterobacteralesimipenem-cilastatin-relebactammultidrug-resistantPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.